Prosecution Insights
Prosecution Insights
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| SHAMEEM, GOLAM M | 1 | 86.6% | +16.0% |
| BELL, SARA ELIZABETH | 1 | 68.5% | +39.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684789 | APPLICATION OF BENZANILIDE COMPOUND IN TUMOR TREATMENT | SEAMAN, D MARGARET M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028574 | Marker for determining anti-cancer effects of mitochondrial oxidative phosphorylation pathway inhibitor | BELL, SARA ELIZABETH | 76d |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | — |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684789 | APPLICATION OF BENZANILIDE COMPOUND IN TUMOR TREATMENT | SEAMAN, D MARGARET M | 1625 | §102§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18684802 | APPLICATION OF BENZISOQUINOLINE DIKETONE COMPOUND IN TREATMENT OF TUMOR | SHAMEEM, GOLAM M | 1621 | §112 | Non-Final OA | — | Pending | Feb 19, 2024 |
| 18028574 | Marker for determining anti-cancer effects of mitochondrial oxidative phosphorylation pathway inhibitor | BELL, SARA ELIZABETH | 1625 | §102§103§112DPOther | Non-Final OA | 76d | Pending | Mar 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial